Steady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adults

Antimicrob Agents Chemother. 2007 Feb;51(2):787-90. doi: 10.1128/AAC.00673-06. Epub 2006 Nov 20.

Abstract

We assessed the pharmacokinetics and interactions of steady-state micafungin (Mycamine) or placebo with steady-state voriconazole in 35 volunteers. The 90% confidence intervals around the least-squares mean ratios for micafungin pharmacokinetic parameters and placebo-corrected voriconazole pharmacokinetic parameters were within the 80%-to-125% limits, indicating an absence of drug interaction.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Adolescent
  • Adult
  • Antifungal Agents / administration & dosage
  • Antifungal Agents / pharmacokinetics*
  • Drug Administration Schedule
  • Drug Interactions
  • Drug Therapy, Combination
  • Echinocandins
  • Female
  • Humans
  • Lipopeptides
  • Lipoproteins / administration & dosage
  • Lipoproteins / pharmacokinetics*
  • Male
  • Micafungin
  • Middle Aged
  • Peptides, Cyclic / administration & dosage
  • Peptides, Cyclic / pharmacokinetics*
  • Pyrimidines / administration & dosage
  • Pyrimidines / pharmacokinetics*
  • Triazoles / administration & dosage
  • Triazoles / pharmacokinetics*
  • Voriconazole

Substances

  • Antifungal Agents
  • Echinocandins
  • Lipopeptides
  • Lipoproteins
  • Peptides, Cyclic
  • Pyrimidines
  • Triazoles
  • Voriconazole
  • Micafungin